191 related articles for article (PubMed ID: 22728262)
1. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.
Broski SM; Hunt CH; Johnson GB; Subramaniam RM; Peller PJ
J Nucl Med; 2012 Aug; 53(8):1200-6. PubMed ID: 22728262
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma.
Fujioka T; Toriihara A; Kubota K; Machida Y; Nakamura S; Kishimoto S; Ohashi I; Shibuya H
Nucl Med Commun; 2014 Aug; 35(8):857-63. PubMed ID: 24751700
[TBL] [Abstract][Full Text] [Related]
3. Preliminary study on the evaluation of olfactory neuroblastoma using PET/CT.
Wu HB; Wang QS; Zhong JM; Zhou WL; Li HS; Qiao-yu W
Clin Nucl Med; 2011 Oct; 36(10):894-8. PubMed ID: 21892040
[TBL] [Abstract][Full Text] [Related]
4. A case of olfactory neuroblastoma detected by (18)F-FDG PET/CT.
Tanaka K; Yamamoto Y; Hoshikawa H; Nishiyama Y
Clin Nucl Med; 2014 Jul; 39(7):635-6. PubMed ID: 24662664
[TBL] [Abstract][Full Text] [Related]
5. High 18F-FDG Avidity of Low-Grade Esthesioneuroblastoma.
Jannin A; Turpin A; Baillet C; Aubert S; Do Cao C
Clin Nucl Med; 2018 Mar; 43(3):e101-e102. PubMed ID: 29293141
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
7. Role of
Elkhatib AH; Soldatova L; Carrau RL; Hachem RA; Ditzel L; Campbell R; Prevedello DM; Prevedello L; Filho LF; Campbell RG
Laryngoscope; 2017 Feb; 127(2):321-324. PubMed ID: 27481043
[TBL] [Abstract][Full Text] [Related]
8. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATATE and 18F-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival Region.
Dadgar H; Norouzbeigi N; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2020 Aug; 45(8):e363-e364. PubMed ID: 32558717
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Adrenal Hyperplasia Due to Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma on FDG PET and 111In-Pentetreotide Scintigraphy.
Matsusaka Y; Nakahara T; Kurihara I; Iwabuchi Y; Jinzaki M
Clin Nucl Med; 2018 Jun; 43(6):452-453. PubMed ID: 29659387
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
12. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
[TBL] [Abstract][Full Text] [Related]
13. F-18 FDG PET/CT staging and posttherapeutic assessment of esthesioneuroblastoma.
Nguyen BD; Roarke MC; Nelson KD; Chong BW
Clin Nucl Med; 2006 Mar; 31(3):172-4. PubMed ID: 16495744
[No Abstract] [Full Text] [Related]
14. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
[TBL] [Abstract][Full Text] [Related]
15. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
16. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.
Picchio M; Mangili G; Samanes Gajate AM; De Marzi P; Spinapolice EG; Mapelli P; Giovacchini G; Sigismondi C; Viganò R; Sironi S; Messa C
Nucl Med Commun; 2010 Jun; 31(6):506-12. PubMed ID: 20168262
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
18. Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer.
Manohar K; Mittal BR; Bhoil A; Bhattacharya A; Singh G
Nucl Med Commun; 2013 Jun; 34(6):557-61. PubMed ID: 23549551
[TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
Manabe O; Hattori N; Hirata K; Itoh K; Hosokawa M; Takahashi H; Oyama-Manabe N; Tamaki N
J Nucl Med; 2013 May; 54(5):670-6. PubMed ID: 23516310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
